Viz.ai launches AI suite for pulmonary care

Viz.ai has launched Viz Pulmonary Suite, an AI-powered platform designed to help health systems coordinate care for pulmonary conditions.

The suite brings acute and chronic pulmonary workflows into a single platform, connecting imaging findings and EHR data with downstream clinical workflows. Viz.ai said the platform is intended to help clinicians identify patients earlier, reduce missed diagnoses, and limit treatment delays.

Pulmonary conditions covered in the suite include chronic obstructive pulmonary disease, lung nodules, and pulmonary embolism. The platform combines pulmonary-specific patient histories, clinical summaries, guideline surfacing, and care coordination tools, according to Viz.ai.

The company said fragmented care pathways remain a challenge for pulmonary teams. Patients may move through imaging, emergency care, acute-care visits, and outpatient follow-up without a unified workflow, increasing the risk that findings are not acted on or that referrals are lost.

Viz.ai cited referral leakage as one reason for the launch, noting that 55% to 65% of potential in-network referrals may be lost due to health system leakage. The company said the suite is designed to improve continuity across the patient journey by linking detection, documentation, decision support, and follow-up tasks.

The pulmonary suite includes Viz PE, the company’s pulmonary embolism module. Viz.ai said Viz PE has been shown in a single-center study to reduce time to treatment from 1.75 days to 0.56 days and lower in-hospital mortality among high-risk pulmonary embolism patients.

Pulmonary embolism is a natural fit for imaging-linked AI workflows because diagnosis often depends on CT pulmonary angiography and timely clinical escalation. Lung nodule management also depends heavily on imaging follow-up, where missed or delayed surveillance can affect care continuity.

“Pulmonary care breaks down not because we lack treatments, but because patients may be lost between moments of care,” said Tim Showalter, MD, chief medical officer of Viz.ai.

Viz.ai also cited broader pulmonary-care gaps. The company said nearly half of patients hospitalized for acute COPD exacerbations are readmitted within 30 days, up to 71% of clinically significant lung nodules may lack appropriate follow-up, and incidental pulmonary emboli can be missed on initial imaging.

The company will present the suite at the American Thoracic Society Annual Conference in Orlando, FL, from May 17 to 19. Its ATS programming includes a session on operationalizing AI-powered pulmonary care across the continuum.

For radiology departments, the launch points to a broader shift in imaging AI. The value proposition is moving beyond single-point detection toward workflow-integrated coordination, where imaging findings are connected to clinical pathways, follow-up management, and health-system retention.